Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 308

1.

Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.

Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva).

J Antimicrob Chemother. 2015 Apr 21. pii: dkv086. [Epub ahead of print]

PMID:
25900159
2.

Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.

Mondi A, Fabbiani M, Ciccarelli N, Colafigli M, D'Avino A, Borghetti A, Gagliardini R, Cauda R, De Luca A, Di Giambenedetto S.

J Antimicrob Chemother. 2015 Jun;70(6):1843-9. doi: 10.1093/jac/dkv037. Epub 2015 Feb 26.

PMID:
25885326
3.

Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model?

Fantoni M, Murri R, Scoppettuolo G, Fabbiani M, Ventura G, Losito R, Berloco F, Spanu T, Sanguinetti M, Cauda R.

Future Microbiol. 2015;10(1):15-20. doi: 10.2217/fmb.14.99.

PMID:
25598334
4.

Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.

Fabbiani M, Grima P, Milanini B, Mondi A, Baldonero E, Ciccarelli N, Cauda R, Silveri MC, De Luca A, Di Giambenedetto S.

Antivir Ther. 2014 Dec 17. doi: 10.3851/IMP2926. [Epub ahead of print]

PMID:
25516553
5.

Baseline CD4+ T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients.

Ciccarelli N, Grima P, Fabbiani M, Baldonero E, Borghetti A, Milanini B, Limiti S, Colafigli M, Tamburrini E, Cauda R, De Luca A, Di Giambenedetto S.

Antivir Ther. 2014 Dec 11. doi: 10.3851/IMP2925. [Epub ahead of print]

PMID:
25504667
6.

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre.

Borghetti A, Mondi A, Piccoli B, Gagliardini R, Lamonica S, Ciccarelli N, D'Avino A, Pallavicini F, Cauda R, De Luca A, Fabbiani M, Di Giambenedetto S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19817. doi: 10.7448/IAS.17.4.19817. eCollection 2014.

7.

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study.

Bianco C, Rossetti B, Gagliardini R, Lamonica S, Fanti L, Lombardi F, Cauda R, Di Giambenedetto S, De Luca A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19816. doi: 10.7448/IAS.17.4.19816. eCollection 2014.

8.

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.

Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, Del Pin B, Mondi A, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19808. doi: 10.7448/IAS.17.4.19808. eCollection 2014.

9.

Liver fibrosis is associated with cognitive impairment in HIV-positive patients.

Ciccarelli N, Fabbiani M, Grima P, Limiti S, Fanti I, Mondi A, Gagliardini R, D'Avino A, Borghetti A, Cauda R, Di Giambenedetto S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19722. doi: 10.7448/IAS.17.4.19722. eCollection 2014.

10.

Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy.

Antinori A, Borderi M, Cauda R, Bini T, Chirianni A, Squillace N, Mancusi D, Termini R.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19573. doi: 10.7448/IAS.17.4.19573. eCollection 2014.

11.

Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk.

D'Avino A, Lassandro A, Lamonica S, Piccoli B, Fabbiani M, Mondi A, Gagliardini R, Borghetti A, Fanti I, Pallavicini F, Cauda R, Di Giambenedetto S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19570. doi: 10.7448/IAS.17.4.19570. eCollection 2014.

12.

Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals.

Borghetti A, Cattani P, Maria G, D'Onghia S, Santangelo R, Marchetti S, Farina S, Cauda R, De Luca A, Di Giambenedetto S.

J Infect. 2015 Jan;70(1):60-71. doi: 10.1016/j.jinf.2014.07.025. Epub 2014 Aug 15.

PMID:
25135229
13.

Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study.

Giannella M, Trecarichi EM, De Rosa FG, Del Bono V, Bassetti M, Lewis RE, Losito AR, Corcione S, Saffioti C, Bartoletti M, Maiuro G, Cardellino CS, Tedeschi S, Cauda R, Viscoli C, Viale P, Tumbarello M.

Clin Microbiol Infect. 2014 Dec;20(12):1357-62. doi: 10.1111/1469-0691.12747. Epub 2014 Aug 11.

PMID:
24980276
14.

Gene Xpert MTB/RIF assay confirms its value in the first multicentre, randomised, controlled trial conducted in primary-care settings in Africa.

Cauda R.

Pathog Glob Health. 2014 Apr;108(3):127. doi: 10.1179/2047772414Z.000000000200. No abstract available.

15.

Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae.

Tumbarello M, Trecarichi EM, Tumietto F, Del Bono V, De Rosa FG, Bassetti M, Losito AR, Tedeschi S, Saffioti C, Corcione S, Giannella M, Raffaelli F, Pagani N, Bartoletti M, Spanu T, Marchese A, Cauda R, Viscoli C, Viale P.

Antimicrob Agents Chemother. 2014 Jun;58(6):3514-20. doi: 10.1128/AAC.02373-13. Epub 2014 Apr 14.

16.

Evaluation of efficacy, pharmacokinetics and tolerability of peptidomimetic aspartic proteinase inhibitors as cream formulation in experimental vaginal candidiasis.

De Bernardis F, Arancia S, Tringali G, Greco MC, Ragazzoni E, Calugi C, Trabocchi A, Sandini S, Graziani S, Cauda R, Cassone A, Guarna A, Navarra P.

J Pharm Pharmacol. 2014 Aug;66(8):1094-101. doi: 10.1111/jphp.12240. Epub 2014 Mar 13.

PMID:
24628362
17.

Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data.

Dello Russo C, Lisi L, Fabbiani M, Gagliardi D, Fanti I, Di Giambenedetto S, Cauda R, Navarra P.

Pharmacogenomics. 2014 Feb;15(3):319-27. doi: 10.2217/pgs.13.242.

18.

Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.

Gagliardini R, Fabbiani M, Fortuna S, Visconti E, Navarra P, Cauda R, Colafigli M, De Luca A, Trecarichi EM, Di Giambenedetto S.

Infection. 2014 Aug;42(4):775-8. doi: 10.1007/s15010-014-0599-z. Epub 2014 Feb 15.

PMID:
24531907
19.

Ophthalmic artery resistance index is increased in HIV-Infected patients and is influenced by protease inhibitors exposure.

Fabbiani M, Grima P, Borghetti A, Colafigli M, D'Avino A, Mondi A, Gagliardini R, De Luca A, Cauda R, Di Giambenedetto S.

J Infect. 2014 May;68(5):500-3. doi: 10.1016/j.jinf.2014.01.012. Epub 2014 Feb 6. No abstract available.

PMID:
24509141
20.

Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis.

De Angelis G, Cataldo MA, De Waure C, Venturiello S, La Torre G, Cauda R, Carmeli Y, Tacconelli E.

J Antimicrob Chemother. 2014 May;69(5):1185-92. doi: 10.1093/jac/dkt525. Epub 2014 Jan 23. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk